Controversies of hepatectomy and adjuvant therapy for hepatocellular carcinoma: moving forward  

作　　者：Jian-Hong Zhong Bang-De Xiang 

机构地区：[1]Department of Hepatobiliary Surgery,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China [2]Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center,Nanning 530021,China

出　　处：《Hepatoma Research》2019年第6期1-6,共6页肝癌研究（英文版）

基　　金：This work was supported by the National Major Special Science and Technology Project(2017ZX10203207);Graduate Course Construction Project of Guangxi Medical University(YJSA2017014);the Foundation Ability Enhancement Project for Young Teachers in Guangxi Universities(2018KY0122),the Guangxi Natural Science Foundation(2018GXNSFBA138018),and Guangxi BaGui Young Scholars.

摘　　要：Due to the prevelence of hepatitis B virus(HBV)and hepatitis C virus(HCV),occurrence of hepatocellular carcinoma(HCC)is increasing in many countries/regions,including China[1].

关 键 词：HEPATOCELLULAR ADJUVANT HEPATITIS 

分 类 号：R73[医药卫生—肿瘤]